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Retrospective Study of Patients with Hyperphenylalaninemia- Experience from
a Tertiary Care Center in Pakistan
Sibtain Ahmed1, Hafsa Majid2, Lena Jafri3, Aysha Habib Khan4, Zeba Zulfiqar Ali5, Bushra Afroze6
Introduction
Disorders of phenylalanine (Phe) metabolism are one of
the most frequently presenting inherited metabolic
disorders (IMDs).1 They are a heterogeneous group of
autosomal recessive disorders due to deficiency of the
enzyme, phenylalanine-4-hydroxylase (PAH) or defects
in the metabolism or regeneration of its cofactor
tetrahydrobiopterin (BH4).2 The BH4 is synthesised from
guanosine triphosphate cyclohydrolase (GTPCH), 6-
pyruvoyl-tetrahydropterin synthase (PTPS), sepiapterin
reductase (SR) and is regenerated by dihydropteridine
reductase (DHPR) and pterin carbinolamine -4-
dehydratase (PCD).3 Neonates with PAH deficiency are
usually asymptomatic at birth except a tendency towards
lower birth weight and smaller head circumference, but,
if left untreated, can present with growth failure, poor
skin pigmentation, microcephaly, seizures, global
developmental delay (DD), severe intellectual deficit (ID)
and movement disorder. Clinical features of BH4 defects
include ID, convulsions, disturbance of tone and posture,
drowsiness, irritability, abnormal movements, recurrent
hyperthermia,  hyper-salivation and swallowing
difficulties,4 however, GTPCH, PTPS, DHPR and PCD
defects have their peculiar biochemical profile.
Hyperphenylalaninemia (HPA) is identified through
quantification of plasma amino acid (PAA). Further
evaluation of HPA occurring as a secondary consequence
of a defect in the metabolism or regeneration of BH4 is
done through analysis of urine or blood neopterin,
biopterin and measurement of DHPR activity.5,6
Differentiation between PAH deficiency and defect in
metabolism or regeneration of BH4 is important for the
initiation of disease-specific treatment, for better
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Abstract
Objective: To assess the clinical and biochemical features as well as outcome of hyperphenylalaninemia
patients.
Methods: The descriptive retrospective study was conducted at the Aga Khan University Hospital,
Karachi, and comprised data from January 2013 to February 2017 of plasma amino acid analysed at
the Biochemical Genetic Laboratory of patients with phenylalanine levels >120 umol/L. Medical
charts of patients registered with the Metabolic Clinics were reviewed, while outside referrals were
contacted by telephone to collect data on a pre-structured questionnaire. Data was analysed using
SPSS 21.
Results: Of the 18 patients, 13(72%) were males. Overall median age was 606 days (interquartile
range: 761) and median phenylalanine levels were 1280 (interquartile range: 935) umol/L. Phenylalanine
hydroxylase deficiency was present in 5(28%) patients while 3(16.6%) had defects in the metabolism
or regeneration of tetrahydrobiopterin. The most common clinical features was intellectual deficit
and seizures 14(78%) each, followed by lighter hair colour 10(55.5%) and hypotonia 11(61%). High
treatment cost was the leading reason for cessation of therapy in 7(39%) followed by refusal by
patient's family 5(28%).
Conclusion: Most hyperphenylalaninemia cases were diagnosed late when intellectual disability
had already developed.
Keywords: Phenylalanine, Hyperphenylalaninemia, Classification, Phenylalanine hydroxylase
deficiency, Tetrahydrobiopterin defects. (JPMA 69:  509; 2019)
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outcomes, carrier screening for high-risk family members,
proper genetic counselling and future reproductive
options for the carriers. Patients with PAH deficiency
require Phe-restricted diet. On the contrary, for BH4
defects, Phe-restricted diet is often not needed but early
supplementation with dopamine and serotonin
precursors, and synthetic BH4 is required to attain
symptomatic improvement.7
The prevalence of HPA due to either deficiency of PAH
enzyme or defects in the metabolism or regeneration of
BH4 is reported to be 1:10,000.8 However, the prevalence
of BH4 deficiency is rare, accounting for 2-3% of HPA
cases.9 The true incidence of HPA in Pakistani population
is unknown. A study reported five cases of HPA 2013-
14.10 Data on the aetiological causes of HPA is lacking
in Pakistan. The current study was planned to assess the
clinical, biochemical features, outcome and aetiology of
patients with HPA.
Material and Methods
The descriptive retrospective study was conducted at the
Section of Clinical Chemistry, Department of Pathology
and Laboratory Medicine, in collaboration with the
Department of Paediatrics and Child Health, Aga Khan
University Hospital (AKUH), Karachi, and comprised data
from January 2013 to February 2017.
Data was related to patients who reported with plasma
Phe levels >120umol/l on PAA.
In the first phase, reports of patients with elevated
Phe>120 umol/L were reviewed by a chemical pathologist
and a metabolic physician. PAA patterns consistent with
liver disease were excluded. The characteristic patterns
of liver diseases on PAA was either elevated Phe, tyrosine,
ornithine, methionine and decreased branched chain
amino acids (leucine, valine, and isoleucine) or  elevated
Phe, tyrosine, methionine and histidine.11 Dissimilarity
exists among different centres on the methodology used
and age of screening for HPA. Also, blood Phe levels, taken
as positive result requiring further investigations, varies
from 120umol/L to 240umol/L.12,13 The cut-off >120
umol/L is used for newborn screening (NBS) done via
Tandem Mass Spectrometry (TMS), but, as we performed
PAA quantification using Biochrom based on high
performance liquid chromatography (HPLC), which is not
a method for NBS, we used the higher cut-off of Phe i.e.
240 umol/L for HPA. In the second phase, medical charts
of patients registered at metabolic clinics were reviewed,
while outside referrals were contacted by telephone to
collect information about further laboratory tests (urine
or blood neopterin, biopterin, DHPR activity or molecular
tests) and treatment received. This was done on a pre-
structured questionnaire.
For PAA analysis, 3-4ml of blood samples was collected
in lithium heparin tube. Samples were transported in dry
ice to the Biochemical Genetic Laboratory (BGL) after
centrifugation from outreach phlebotomy centres. All
samples were stored at -20°C prior to analysis. A
questionnaire focussing on clinical and biochemical
information was filled for the in-patients and for patients
whose samples were received at the phlebotomy centres
of AKUH.
The quantification was performed by cation-exchange
HPLC (Biochrom 30+ model 440/570 nm), with a lithium
column of 4.6mm diameter. Standard, control and
specimens were deproteinised with sulfosalicylic acid 10%
and norleucine was added as internal standard. The results
were analysed by EZ chrome software 3.31. Quality control,
validation and proficiency testing validation for amino
acids were accomplished according to Clinical and
Laboratory Standards Institution (CLSI) guidelines.14 Two
levels of commercially available controls were run with
each batch of 10 samples.
Study was commenced after approval was obtained from
the institutional ethics committee.
Data was analysed using SPSS 21. Frequencies and
percentages were calculated for gender, consanguinity,
clinical presentations, biochemical features and
aetiological classification of HPA. Data for age and blood
Phe levels was skewed and, hence, median and
interquartile ranges (IQR) were calculated.
Results
Over the period under review, 3057 patients were tested
for PAA. Of them, 34(1.1%) had Phe levels >120 umol/l
and comprised the initial sample. Subsequently, 12(35%)
patients showing PAA pattern consistent with liver disease
and 4)11%) with missing data were excluded. The final
sample had 18(53%) patients (Figure 1). Of them, 4 (22%)
patients had expired.
There were 13(72%) males and 5(28%) females. Median
age of the males and females were 547 days (IQR: 592)
and 665 days (IQR: 2491) respectively. Overall median Phe
level was 1280 (IQR: 935) umol/L. Parental consanguinity
was observed in 17(94.4%) patients.
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Further diagnostic testing, including
blood pterin levels and DHPR activity, was
done in 8(44%) cases while the rest were
not advised further workup by their
primary physicians. The most common
clinical features recorded were ID 14(78%)
and seizures 14(78%), followed by
hypotonia 11(61%) and lighter hair colour
10(56%) Figure 2) . No significant
correlation was found between a
particular presenting feature and disease
type (p>0.05).
There were 5(28%) patients with PAH
deficiency who were started on a Phe-
restricted natural diet, Phe-omitted amino
acids mixture and symptomatic treatment
comprising anti-convulsants and muscle relaxants. In
1(20%) patient, treatment was discontinued after 4-5
months due to non-acceptability of treatment by the
family.
L-dopa, 5-hydroxy (OH) tryptophan and folinic acid and
symptomatic treatment of anti-convulsants and muscle
relaxants was advised to 2(11%) patients with DHPR
deficiency. However 1(50%) patient failed to continue
treatment after 1.5 years due to unavailability of
medications.
There were 2(11%) patients with GTPCH deficiency who
were started on treatment with L-dopa, 5-OH
tryptophan and BH4 and symptomatic treatment of
anti-convulsants and muscle relaxants, which was
discontinued by parents after 1 year due to
unaffordability.
Patients with HPA who were not further evaluated were
categorised as unclassified HPA 10(55.5%). In this group,
5(50%) patients were advised Phe-restricted diet based
on low protein diet with no meat, egg and milk, which
was followed only by 2(40%) patients. However, no
treatment was advised by the physicians in 5(50%) cases.
The high cost of treatment was the leading reason for
cessation of therapy 7(38%) patients, followed by non-
acceptability by patient's family 5(28%) (Figure 3).
Discussion
Patients with HPA must be diagnosed and treated before
manifestation of clinical symptoms to prevent ID. Asia-
Pacific countries, including Pakistan, Bangladesh and
J Pak Med Assoc
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Figure-1:   Flowchart showing frequency and outcome of patients with hyperphenylalaninemia (n=34).
Figure-2:   Clinical features of patients with phenylalanine hydroxylase enzyme deficiency
or defects in metabolism / regeneration of tetrahydrobioptern (n=18).
*Defects in metabolism/regeneration of tetrahydrobiopterin
include DHPR and GTPCH deficiency.
Figure-3:   Reasons for cessation of therapy in patients with
Phenylalanine hydroxylase enzyme deficiency or defects in
metabolism/regeneration of tetrahydrobiopterin (n=14).
India, with large numbers of births lack a comprehensive
NBS programme for inherited metabolic disorders
(IMDs).15,16 The older age of presentation of most patients
in this study points to the fact these patients were screened
for IMDs when they already had irreversible ID. The
prevalence of HPA is higher in Turks (1 in 2600 live births)
and Saudi Arabia (1 in 6000) due to consanguinity
compared to Caucasian countries like Finland where
occurrence is as low as 1 in 200000 births.5,17,18 Most
physicians in Pakistan usually do not evaluate patients
with ID for IMDs. Patients are often evaluated for IMD in
clinical presentation of 'metabolic crisis' or 'neuro-
regression'. Whereas, patients with HPA neither present
with 'metabolic crisis' nor 'neuro-regression' but the classic
presentation of HPA is ID, seizures and movement
disorders. Thus diagnosis of HPA is missed in Pakistan and
could be a reason of less number of cases compared to
the Turks and Saudis with similar rates of consanguinity.
The importance of screening individuals with ID for HPA
is demonstrated in an Iranian study undertaken in
institutionalised individuals, where the prevalence of HPA
was fund to be 4%.19
Literature search shows that PAH deficiency is the most
common HPA encountered compared to the prevalence
of BH4 deficiency, which constitutes about 3% of HPA
cases.20 In our study, PAH deficiency was the most common
cause of HPA.
Urine or blood pterins and DHPR activity was done in only
8 cases and all were followed up by a metabolic physician.
This could be due to the local non-availability of the pterins
analysis and DHPR activity needed for the aetiological
work-up of HPA in Pakistan, logistic limitations in
outsourcing of these tests to overseas labs, and lack of
awareness of the general paediatricians about the
diagnostic approach for HPA. Classification of HPA is
essential because the prognosis, treatment and outcome
of BH4 defects and PAH deficiency is different from each
other. Not all HPAs need dietary treatment which is age
and gender-specific, like Phe-restricted diet is required in
PAH deficiency but is not needed in BH4 defects, in which
dopamine and serotonin precursors and synthetic BH4 is
needed.21,22
Majority of the patients either did not start treatment or
discontinued Phe-restricted diet mainly due to financial
constraints and non-acceptability of the food for special
medical purpose (FSMP) by the families who did not
accept the concept of diet modification as a treatment.
Lack of knowledge of patient families about the
consequences of the disorder and potential benefits of
treatment, superimposed by high cost, are reported as a
common factor leading to noncompliance to treatment
regimens.23,24  An estimated average monthly treatment
cost for a patient needing FSMP in Pakistan ranges from
€400-€1000, owing to the high tax imposed by the
government on its import. This often creates a dilemma
for families to sustain a l i fe- long treatment.
There were certain limitations to our study. Firstly, most
patients were referred to the centre for diagnostic
evaluation because of a suspected IMD in clinical
presentation of 'metabolic crisis' or 'neuro-regression'.
Therefore, the results may not be generalised to the
community or non-referred samples. Secondly, the sample
size was small, limiting the power of the study and there
is a likelihood that significant correlation between a
particular presenting feature and disease type may arise
with larger sample size.
Conclusion
There is need for local availability of pterin analysis and
DHPR activity for easy access to physicians who can follow
the appropriate diagnostic approach for patients with
HPA. The outcome of patients with HPA due to PAH
deficiency can be improved significantly with early
detection through NBS allowing early intervention, which
has to be sustainable.
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